Provided herein are methods and compositions for the production of hepatocytes from placenta stem cells. Further provided herein is the use of such hepatocytes in the treatment of, and intervention in, for example, trauma, inflammation, and degenerative disorders of the liver. Also provided herein are compositions and methods relating to combinations of nanofibrous scaffolds and adherent placental stem cells and methods of using the same in cartilage repair. Finally, provided herein are compositions and methods relating to nonadherent, CD34.sup.+CD45.sup. stem cells from placenta.

The present disclosure relates to exosome systems and compositions and preservative systems and compositions as well as methods of use and methods of manufacturing of them.

The present invention relates to a method for producing a culture medium-derived component or a crystallized culture medium using a PCA (Precipitation with Compressed Fluid Anti-solvent) drying process, a method for restoring chondrocytes using the culture medium-derived component or the crystallized culture medium prepared by way of the above method, a method for treating a subject having osteoarthritis by way of the method for restoring chondrocytes using the culture medium-derived component or the crystallized culture medium, a method for treating a subject having osteoarthritis using the culture medium-derived component or the crystallized culture medium, and the use of the culture medium-derived component or the crystallized culture medium for the treatment of osteoarthritis. The culture medium-derived component provided in the present invention has excellent activity of alleviating inflammatory environment and inhibiting expression of catabolism-related genes, and the culture medium-derived component can be produced in a higher yield by way of the method provided in the present invention, and thus can be widely used in the development of therapeutic agents for osteoarthritis.

The methods and compositions described herein relate to producing, expanding, enriching, and/or maintaining hematopoietic stem cells ex vivo by treating the cells with an agent(s) that exhibits two or more activities selected from modulation of histone methylation; inhibition of TGF signaling; inhibition of p38 signaling; activation of canonical Wnt signaling; and modulation of histone acetylation. In some embodiments, the technology described herein relates to transplantation of hematopoietic stem cells.

Provided herein are methods and compositions for the production of hepatocytes from placenta stem cells. Further provided herein is the use of such hepatocytes in the treatment of, and intervention in, for example, trauma, inflammation, and degenerative disorders of the liver. Also provided herein are compositions and methods relating to combinations of nanofibrous scaffolds and adherent placental stem cells and methods of using the same in cartilage repair. Finally, provided herein are compositions and methods relating to nonadherent, CD34.sup.+CD45.sup. stem cells from placenta.

Provided in the present invention is a cell freezing medium for clinical use. In particular, the cell freezing medium of the present invention comprises the following components: (1) human albumin; (2) cryoprotectant: the cryoprotectant comprises a combination of one or more of dimethyl sulfoxide, glycerol, and ethylene glycol; (3) a saline buffer; wherein the salt buffer is a solution containing Na.sup.+, K.sup.+, Mg.sup.+, Cl.sup., and CH.sub.3COO.sup. ions; (4) a vitamin; and (5) an amino acid, wherein the human albumin concentration is 1%-20% (w/v). The cell, after long-term cryopreservation with the freezing medium of the present invention, has a high viability, and the cellular efficiency maintains a high uniformity. The grade of purity of the freezing medium of the present invention is the pharmaceutical grade or USP grade; and the freezing medium is safe and reliable for clinical use, and can be used or conventional adherent and suspension cells.

Methods, compositions, and devices to limit, modulate, insulate, and/or otherwise alter the effects of exogenous physical stimuli on cells are described herein. The cells may be removed from the body, preferably isolated, and treated ex vivo with the composition to limit the effects of physical stimuli on the cells and then returned to the patient. Alternatively, the cells may be treated in vivo. The compositions can be administered a variety of manners, such as systemically, locally or regionally.

This application relates to non-human primate (NHP) induced pluripotent stem cell (IPSC)-derived hepatocytes and methods of producing the same. Moreover, this application relates to methods of using NHP IPSC-derived hepatocytes for drug screening, drug safety assessment and in models of infection.

The present invention relates to the use of a combination of: (i) a macromolecular erythrocyte sedimentation enhancer, and (ii) dimethyl sulphoxide (DMSO), dimethylglycine (DMG) and/or valine;
to recover non-erythrocyte blood cells from a blood cell-containing sample and/or to prime non-erythrocyte blood cells to protect their integrity in subsequent cryopreservation step(s).

The method for the manufacture of a composition for the treatment of osteoarthritis in subjects involves the use of mesenchymal stem cells (MSC). These MSCs are derived from at least two healthy donors who are different from the subject to be treated. The MSCs are morphologically healthy and substantially free of senescent cells. They are also free of pathogens characteristic of the species and possess the main characteristics of MSCs. During propagation, the cumulative population doubling value (CPD value) of the MSCs is preferably in the range of 3 to 14. The level of kynurenine metabolite production of the MSCs is in the range of 30 to 50 ng/ml, and the level of THBS1 cytokine production of the MSCs is in the range of 50 to 80 ng/ml. The number of cells used is in the range of 105 to 5?107.